53P - Targeting ER-Golgi homeostasis is an advantageous therapeutic strategy in lung cancer: synergistic interaction of HSP90 antagonist and proteasome in...

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Lung and other Thoracic Tumours
Translational Research
Presenter Maya Gottfried
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors M. Gottfried1, L. Drucker2, V. Zismanov3
  • 1Oncology, Meir Medical Center, 44281 - Kfar Saba/IL
  • 2Oncogenetic Laboratory, Meir Medical Center, Kfar Saba/IL
  • 3Lung Cancer Research Laboratory, Meir Medical Center, Kfar Saba/IL


Lung cancer remains the most common cause of cancer-related death worldwide. This malignancy is a complex disease, and it is important to identify potential biological targets, the blockade of which would affect multiple downstream signaling cascades. A growing number of reports recognize novel therapeutic targets in the protein homeostasis network. These include the heat shock protein 90 (Hsp90) essential to posttranslational folding and maturation of multiple oncogenic kinases, and the proteasome that orchestrates the turnover of innumerable cellular proteins. Previous studies demonstrate that targeting Hsp90 or the proteasome separately has anti-non small cell lung cancer (NSCLC) activity. Here, we explored whether combined administration of Hsp90 and proteasome inhibitors promotes the anti-NSCLC activity of the drugs by augmenting disruption of ER-Golgi homeostasis.